Metagenomi to Present Preclinical APOC3 Data at Nature Conference

Metagenomi will present preclinical data at the Nature Conference "Cracking the Code: Nucleic Acid Medicines Coming of Age" supporting its collaboration with Ionis Pharmaceuticals on APOC3, a new target for treating severe hypertriglyceridemia. The data will be presented by Alan Brooks, PhD, Senior Vice President of Research at Metagenomi, on December 8, 2025, at 2:45 p.m. EST. The presentation will highlight the potential of CRISPR/Cas-mediated APOC3 knockout as a one-time treatment for severe hypertriglyceridemia.